New User?
Close this box
Login to Your Account
OR
Your Username
Your Password
Forget your Password?.

Neighborbee

 
 
 
< Back

TQQXKaefuezH

Posted Monday, November 23rd, 2015 at 7:05 pm by in .Edit this post More in

perfect design thanks essay on my ambition in life to become a professor The primary endpoint of improved overall survival was met in the RAINBOW trial. In the REGARD trial, single-agent ramucirumab improved overall survival and progression-free survival in patients with advanced gastric cancer who have had disease progression after initial chemotherapy. The primary endpoint in the ROSE trial was not met because progression-free survival with the use of ramucirumab in women with locally recurrent or metastatic breast cancer was not statistically significant. The interim analysis for overall survival in this trial showed no benefit for ramucirumab.

Comments are closed.

 
Home Hives Articles The Bee Blog About Help Sign Up    Log In
Terms and Conditions | Privacy Policy

©2013 Neighborbee, LLC.